• In March 2026, Jabil Inc. reported second-quarter results showing year-on-year growth in sales and net income, and issued third-quarter guidance calling for net revenue between US$8.10 billion and US$8.90 billion, U.S. GAAP operating income of US$398 million to US$458 million, and diluted EPS of US$2.36 to US$2.76.
• The company also lifted its full-year fiscal 2026 outlook to US$34.00 billion in revenue, underscoring how healthcare exposure and injector-pen manufacturing for weight-loss drugs are becoming increasingly important to its earnings mix.
• Now we’ll consider how Jabil’s raised full-year 2026 revenue outlook to US$34.00 billion might reshape its medium-term investment narrative.

Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

Jabil Investment Narrative Recap

To own Jabil, you need to believe it can keep shifting its manufacturing mix toward higher value areas like healthcare and AI hardware while managing volatility in weaker markets such as EVs and renewables. The raised full year 2026 revenue outlook to US$34.00 billion reinforces the current earnings momentum, but does not materially change the key near term swing factor, which remains demand and pricing in its new healthcare and injector pen programs, or the biggest risk, which is tariff and trade uncertainty affecting customer demand.

The most relevant update here is Jabil’s new third quarter 2026 guidance, calling for net revenue of US$8.10 billion to US$8.90 billion and U.S. GAAP diluted EPS of US$2.36 to US$2.76. This guidance offers a shorter term reference point for how quickly the healthcare and photonics opportunities could offset pressure in areas like renewable energy and EV related programs, and how effectively the company can protect margins while inventory and tariff risks remain in focus.

But investors should also be aware that potential tariffs involving China, Canada, and Mexico could still...

Jabil’s narrative projects $41.7 billion revenue and $1.5 billion earnings by 2029.

Uncover how Jabil's forecasts yield a $293.11 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$293 to US$376 per share, showing how far apart informed views can be. Against this backdrop, Jabil’s heavier tilt toward higher value healthcare manufacturing and related injector pen demand could matter more for future performance than any single headline number, so it is worth weighing several viewpoints before reaching a conclusion.

Explore 3 other fair value estimates on Jabil - why the stock might be worth as much as 38% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Jabil research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Jabil research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Jabil's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 61 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.